The New England Journal of Medicine September 15, 2011

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger et al.

Bottom Line

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less major bleeding, and resulted in lower all-cause mortality.

Key Findings

1. The primary efficacy outcome of stroke or systemic embolism occurred in 1.27% per year in the apixaban group versus 1.60% per year in the warfarin group (HR 0.79; 95% CI, 0.66 to 0.95; P=0.01 for superiority).

2. Major bleeding (the primary safety outcome) was significantly reduced with apixaban, occurring at a rate of 2.13% per year compared to 3.09% per year with warfarin (HR 0.69; 95% CI, 0.60 to 0.80; P<0.001).

3. All-cause mortality was significantly lower in the apixaban group (3.52% per year) compared to the warfarin group (3.94% per year) (HR 0.89; 95% CI, 0.80 to 0.99; P=0.047).

4. Hemorrhagic stroke was nearly halved by apixaban, occurring at 0.24% per year versus 0.47% per year with warfarin (HR 0.51; 95% CI, 0.35 to 0.75; P<0.001).

5. The rate of ischemic or uncertain stroke was statistically similar between the two groups (0.97% per year for apixaban vs. 1.05% per year for warfarin; HR 0.92; 95% CI, 0.74 to 1.13; P=0.42).

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

18,201

Patients

Duration

1.8 years

Median

Setting

39 countries

Population Patients with atrial fibrillation or atrial flutter and at least one additional risk factor for stroke.

Intervention Apixaban 5 mg twice daily (reduced to 2.5 mg twice daily in patients with at least two of the following: age >=80 years, body weight <=60 kg, or serum creatinine >=1.5 mg/dL).

Comparator Dose-adjusted warfarin (target INR 2.0 to 3.0).

Outcome Composite of ischemic or hemorrhagic stroke or systemic embolism.

Study Limitations

• Patients in the warfarin group had a median time in therapeutic range (TTR) of 66%; while in line with real-world practice, perfectly managed warfarin could potentially narrow the efficacy and safety gaps.

• The trial excluded patients with severe renal impairment (creatinine clearance <25 mL/min), limiting the generalizability of the findings to patients with end-stage renal disease.

• The median follow-up of 1.8 years was relatively short for a lifelong condition, necessitating reliance on subsequent post-marketing registries for long-term safety data.

• There was no active comparator arm with another direct oral anticoagulant (DOAC), preventing definitive head-to-head conclusions between apixaban, rivaroxaban, and dabigatran.

Clinical Significance

The ARISTOTLE trial was paradigm-shifting, demonstrating a rare 'triple crown' of clinical trial benefits: superior efficacy, superior safety, and a mortality benefit compared to the historical gold standard. These results established apixaban as a preferred first-line anticoagulant for stroke prevention in nonvalvular atrial fibrillation, sparing millions of patients the burden of frequent INR monitoring while providing a safer and more effective therapeutic profile.

Historical Context

For decades, vitamin K antagonists like warfarin were the only highly effective oral agents for preventing stroke in atrial fibrillation. However, their use was notoriously difficult due to narrow therapeutic indexes, food/drug interactions, and the need for constant laboratory monitoring. At the time ARISTOTLE was conducted, newer direct oral anticoagulants (DOACs) such as dabigatran (RE-LY, 2009) and rivaroxaban (ROCKET AF, 2011) had just demonstrated non-inferiority to warfarin. ARISTOTLE cemented the DOAC revolution by proving that a direct factor Xa inhibitor (apixaban) was definitively superior to warfarin across multiple key endpoints.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the mechanism of action of apixaban differ from warfarin, and how does this pharmacologic difference explain the lack of need for routine coagulation monitoring in the ARISTOTLE trial?

Key Response

Apixaban directly and reversibly inhibits factor Xa, predictably blocking the coagulation cascade without relying on the depletion of vitamin K-dependent factors. This results in a predictable dose-response curve and rapid onset/offset, eliminating the need for routine INR monitoring required for warfarin.

Resident

If a patient on warfarin for atrial fibrillation with a poor time-in-therapeutic range (TTR) presents to your clinic, what specific clinical factors from the ARISTOTLE trial would you use to justify switching them to apixaban, and how would you execute this transition?

Key Response

ARISTOTLE demonstrated apixaban's superiority in stroke prevention and lower bleeding risk, which is especially beneficial for patients with erratic INRs. To transition, warfarin should be discontinued and apixaban started only when the INR drops below 2.0 to minimize overlapping bleeding risks.

Fellow

The ARISTOTLE trial utilized specific dose-reduction criteria (2.5 mg BID) for certain patients. How do the criteria for apixaban dose reduction reflect its pharmacokinetic profile, and how does renal impairment alter the risk-benefit ratio of apixaban versus warfarin?

Key Response

Apixaban is approximately 25% renally cleared. Dose reduction requires two of three criteria: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Subgroup analyses showed apixaban maintained its safety and efficacy benefits even in CKD, which is critical since warfarin is difficult to manage in renal impairment due to fluctuating INRs and vascular calcification risks.

Attending

While ARISTOTLE showed apixaban reduced mortality, stroke, and major bleeding, how do you weigh the medication cost and the nuances of reversal agents when counseling an elderly patient with a high fall risk?

Key Response

Attendings must balance trial efficacy with real-world practicality. ARISTOTLE showed a significant reduction in intracranial hemorrhage with apixaban compared to warfarin. Therefore, apixaban is generally much safer for high-fall-risk elderly patients, which often outweighs the concerns regarding the high cost or availability of its specific reversal agent, andexanet alfa.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The ARISTOTLE trial utilized a hierarchical testing strategy, first testing for non-inferiority, then superiority for the primary efficacy endpoint, followed by superiority for major bleeding and mortality. What are the statistical advantages of this closed testing procedure regarding Type I error?

Key Response

Hierarchical (closed) testing allows researchers to test multiple hypotheses in a pre-specified order without adjusting the alpha level for multiple comparisons. If non-inferiority is met, they test superiority. If any test fails, subsequent tests are deemed exploratory, strictly preserving the overall 5% family-wise error rate.

Journal Editor

A frequent critique of DOAC trials is the quality of warfarin management in the control arm. In ARISTOTLE, the mean time in therapeutic range (TTR) for the warfarin group was 62%. Could this moderate control-arm performance have exaggerated the superiority of apixaban?

Key Response

A TTR of 62% is standard for global clinical trials but lower than optimal management in highly specialized anticoagulation clinics. A rigorous editor would probe whether apixaban is superior to optimally managed warfarin or just average warfarin management, though ARISTOTLE's center-level TTR subgroup analyses still supported apixaban's bleeding benefits.

Guideline Committee

Based on the mortality, stroke prevention, and bleeding benefits demonstrated in ARISTOTLE, how should current AF management guidelines rank DOACs versus VKAs, and what specific patient populations are excluded from this recommendation?

Key Response

Major guidelines (ACC/AHA/HRS) elevated DOACs like apixaban to a Class I recommendation over warfarin for AF, largely driven by ARISTOTLE's demonstration of lower mortality and reduced intracranial hemorrhage. However, guidelines explicitly exclude patients with moderate-to-severe mitral stenosis or mechanical heart valves, for whom warfarin remains the absolute standard of care.

Clinical Landscape

Noteworthy Related Trials

2009

RE-LY Trial

n = 18,113 · NEJM

Tested

Dabigatran 110mg or 150mg twice daily

Population

Patients with atrial fibrillation and risk for stroke

Comparator

Warfarin

Endpoint

Stroke or systemic embolism

Key result: Dabigatran 150mg reduced stroke and systemic embolism compared to warfarin with similar major bleeding, while 110mg had similar efficacy with lower bleeding.

2011

ROCKET AF Trial

n = 14,264 · NEJM

Tested

Rivaroxaban 20mg once daily

Population

Patients with nonvalvular atrial fibrillation at moderate-to-high risk for stroke

Comparator

Warfarin

Endpoint

Stroke or systemic embolism

Key result: Rivaroxaban was noninferior to warfarin for stroke or systemic embolism prevention, with no significant difference in rates of major bleeding.

2013

ENGAGE AF-TIMI 48 Trial

n = 21,105 · NEJM

Tested

Edoxaban 30mg or 60mg once daily

Population

Patients with atrial fibrillation and moderate-to-high risk of stroke

Comparator

Warfarin

Endpoint

Stroke or systemic embolism

Key result: Both doses of edoxaban were noninferior to warfarin for preventing stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis